Open access
Open access
Powered by Google Translator Translator

Oncology (All Articles)

RCT: Endoscopic surgery improves survival compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma

28 Feb, 2021 | 20:45h | UTC

Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet Oncology

Commentary: Endoscopic Nasopharyngectomy vs IMRT for Previously Treated, Resectable, Locally Recurrent Nasopharyngeal Carcinoma – The ASCO Post

 


CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

26 Feb, 2021 | 08:31h | UTC

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma – Dana-Farber Cancer Institute

Original study: Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma – New England Journal of Medicine

 


Integrated palliative and oncology care for patients receiving treatment for acute myeloid leukemia

26 Feb, 2021 | 08:25h | UTC

Integrated Palliative and Oncology Care for Patients Receiving Treatment for Acute Myeloid Leukemia – The ASCO Post

Original article: Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

 


Randomized trial: Oral Azacitidine maintenance therapy for acute myeloid leukemia in first remission

26 Feb, 2021 | 08:23h | UTC

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Maintenance Oral Azacitidine for Patients With AML in First Remission: QUAZAR AML-001 Trial – The ASCO Post

 


ASCO Guideline: Management of dyspnea in advanced cancer

24 Feb, 2021 | 02:10h | UTC

Management of Dyspnea in Advanced Cancer: ASCO Guideline – Journal of Clinical Oncology

 

Commentary on Twitter (thread – click for more)

 


SR: Delays and disruptions in cancer health care due to COVID-19 pandemic

24 Feb, 2021 | 02:46h | UTC

Delays and Disruptions in Cancer Health Care Due to COVID-19 Pandemic: Systematic Review – JCO Global Oncology

Commentary: COVID-19 Pandemic Caused Delays in Cancer Care – DocWire News

 

Commentary on Twitter

 


Gastroesophageal reflux disease is linked with higher risks of larynx and esophageal cancers

24 Feb, 2021 | 02:00h | UTC

Gastroesophageal reflux disease is linked with higher risks of larynx and esophageal cancers – News Medical

Original study: Gastroesophageal reflux disease: A risk factor for laryngeal squamous cell carcinoma and esophageal squamous cell carcinoma in the NIH‐AARP Diet and Health Study cohort – Cancer

 


Guidelines in the management of CNS tumors

23 Feb, 2021 | 01:09h | UTC

Guidelines in the management of CNS tumors – Journal of Neuro-Oncology

 


Clinical practice guidelines for BRCA1 and BRCA2 genetic testing

21 Feb, 2021 | 21:43h | UTC

Clinical practice guidelines for BRCA1 and BRCA2 genetic testing – European Journal of Cancer

 

Commentary on Twitter

 


Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update

21 Feb, 2021 | 21:47h | UTC

Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update – Journal of Clinical Oncology

 


Review: Diagnosis and treatment of metastatic colorectal cancer

19 Feb, 2021 | 02:07h | UTC

Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review – JAMA (free for a limited period)

 


Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

19 Feb, 2021 | 02:04h | UTC

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update – Journal of Clinical Oncology

 


Review: Optimal supportive care for patients with metastatic breast cancer according to their disease progression phase

18 Feb, 2021 | 02:35h | UTC

Optimal Supportive Care for Patients With Metastatic Breast Cancer According to Their Disease Progression Phase – JCO Oncology Practice

 


RCT: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%

18 Feb, 2021 | 02:34h | UTC

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial – The Lancet

 

Commentary on Twitter

 


Editorial: Bundled payment models in oncology

17 Feb, 2021 | 01:16h | UTC

Editorial: Bundled Payment Models in Oncology: Learning to Think in New Ways – JCO Oncology Practice

Counterpoint: Oncology Care Model: A Herculean Effort With Fixable Fatal Flaws – JCO Oncology Practice

 


Review: Breast cancer in adolescent and young adult women under the age of 40 years

17 Feb, 2021 | 01:13h | UTC

Breast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years – JCO Oncology Practice

 


M-A: Role of diet in colorectal cancer incidence

17 Feb, 2021 | 01:12h | UTC

Role of Diet in Colorectal Cancer Incidence: Umbrella Review of Meta-analyses of Prospective Observational Studies – JAMA Network Open

 


Preliminary study suggests there may be a role for prostate cancer screening with magnetic resonance imaging

16 Feb, 2021 | 01:50h | UTC

Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study – JAMA Oncology

Commentaries: Short MRI Protocol Could Be Alternative for Prostate Cancer Follow-Up – Diagnostic Imaging AND Short MRI exam shows promise for prostate cancer screening follow-up – AuntMinnie (free registration required)

 

Commentary on Twitter

 


RCT: Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer

16 Feb, 2021 | 01:44h | UTC

Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial – The Lancet Oncology (link to abstract – $ for full-text)

 


ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer

15 Feb, 2021 | 00:49h | UTC

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer – Blood Advances

Commentary: ASH 2021 Guidelines for Prevention and Treatment of Venous Thromboembolism in Patients With Cancer – The ASCO Post

 


RCT: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

15 Feb, 2021 | 00:36h | UTC

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Immunotherapy – targeted drug combination improves survival in advanced kidney cancer – Dana-Farber Cancer Institute

 

Commentary on Twitter

 


RCT: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

15 Feb, 2021 | 00:34h | UTC

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: 2021 Genitourinary Cancers Symposium: Enfortumab Vedotin-ejfv Prolongs Survival in Patients With Metastatic Urothelial Carcinoma – The ASCO Post

 


RCT: A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma

15 Feb, 2021 | 00:32h | UTC

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Cabozantinib most effective treatment for metastatic papillary kidney cancer – MedicalXpress

 


Long-term data: No difference in cardiovascular mortality or morbidity with transdermal estradiol vs. LHRH agonists for androgen suppression in prostate cancer

15 Feb, 2021 | 00:31h | UTC

Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme – The Lancet (link to abstract – $ for full-text)

 


RCT: Radiopharmaceutical therapy vs. cabazitaxel in patients with metastatic castration-resistant prostate cancer

15 Feb, 2021 | 00:29h | UTC

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Radionuclide Tx Wins in Third-Line Metastatic CRPC – MedPage Today

 


Stay Updated in Your Specialty

No spam, just news.